These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 30289152

  • 1. Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.
    Gonzalez-Aguilar A, Reyes-Moreno I, Peiro-Osuna RP, Hernandez-Hernandez A, Gutierrez-Aceves A, Santos-Zambrano J, Guerrero-Juarez V, Lopez-Martinez M, Castro-Martinez E.
    Rev Neurol; 2018 Oct 16; 67(8):293-297. PubMed ID: 30289152
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T.
    J Clin Oncol; 2006 Jun 20; 24(18):2715-22. PubMed ID: 16782911
    [Abstract] [Full Text] [Related]

  • 3. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
    Intergroup Radiation Therapy Oncology Group Trial 9402University of Calgary, Calgary, Alberta, Canada; e-mail: jgcairnx@ucalgary.ca, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W.
    J Clin Oncol; 2006 Jun 20; 24(18):2707-14. PubMed ID: 16782910
    [Abstract] [Full Text] [Related]

  • 4. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
    Esteyrie V, Dehais C, Martin E, Carpentier C, Uro-Coste E, Figarella-Branger D, Bronniman C, Pouessel D, Ciron DL, Ducray F, Moyal EC, Network P.
    Oncologist; 2021 May 20; 26(5):e838-e846. PubMed ID: 33524191
    [Abstract] [Full Text] [Related]

  • 5. Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
    Lassman AB.
    CNS Oncol; 2015 May 20; 4(5):341-6. PubMed ID: 26544062
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
    van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K.
    J Clin Oncol; 2013 Jan 20; 31(3):344-50. PubMed ID: 23071237
    [Abstract] [Full Text] [Related]

  • 7. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
    Webre C, Shonka N, Smith L, Liu D, De Groot J.
    Anticancer Res; 2015 Oct 20; 35(10):5467-72. PubMed ID: 26408710
    [Abstract] [Full Text] [Related]

  • 8. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
    van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B.
    Ann Oncol; 2003 Apr 20; 14(4):599-602. PubMed ID: 12649108
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.
    Streffer J, Schabet M, Bamberg M, Grote EH, Meyermann R, Voigt K, Dichgans J, Weller M.
    J Neurol; 2000 Apr 20; 247(4):297-302. PubMed ID: 10836623
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
    Buckner JC, Gesme D, O'Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R.
    J Clin Oncol; 2003 Jan 15; 21(2):251-5. PubMed ID: 12525516
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
    Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, Sabel MC, Wick A, Koeppen S, Ketter R, Vajkoczy P, Eyupoglu I, Kalff R, Pietsch T, Happold C, Galldiks N, Schmidt-Graf F, Bamberg M, Reifenberger G, Platten M, von Deimling A, Meisner C, Wiestler B, Weller M, Neurooncology Working Group (NOA) of the German Cancer Society.
    Neuro Oncol; 2016 Nov 15; 18(11):1529-1537. PubMed ID: 27370396
    [Abstract] [Full Text] [Related]

  • 14. Initial chemotherapy in gliomatosis cerebri.
    Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, Gervais H, Laigle F, Carpentier A, Mokhtari K, Taillandier L, Chinot O, Duffau H, Honnorat J, Hoang-Xuan K, Delattre JY, ANOCEF group.
    Neurology; 2004 Jul 27; 63(2):270-5. PubMed ID: 15277619
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Initial treatment patterns over time for anaplastic oligodendroglial tumors.
    Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.
    Neuro Oncol; 2012 Jun 27; 14(6):761-7. PubMed ID: 22661585
    [Abstract] [Full Text] [Related]

  • 20. Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
    Wick A, Sander A, Koch M, Bendszus M, Combs S, Haut T, Dormann A, Walter S, Pertz M, Merkle-Lock J, Selkrig N, Limprecht R, Baumann L, Kieser M, Sahm F, Schlegel U, Winkler F, Platten M, Wick W, Kessler T.
    BMC Cancer; 2022 Jun 13; 22(1):645. PubMed ID: 35692047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.